- Home
- CADL vs AQST Comparison
CADL vs AQST Comparison
Compare CADL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- AQST
- Stock Information
- Founded
- CADL 1999
- AQST 2004
- Country
- CADL United States
- AQST United States
- Employees
- CADL N/A
- AQST N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- AQST Health Care
- Exchange
- CADL Nasdaq
- AQST Nasdaq
- Market Cap
- CADL 306.4M
- AQST 274.4M
- IPO Year
- CADL 2021
- AQST 2018
- Fundamental
- Price
- CADL $8.09
- AQST $3.24
- Analyst Decision
- CADL Strong Buy
- AQST Strong Buy
- Analyst Count
- CADL 4
- AQST 7
- Target Price
- CADL $21.00
- AQST $10.57
- AVG Volume (30 Days)
- CADL 918.0K
- AQST 1.4M
- Earning Date
- CADL 03-13-2025
- AQST 03-05-2025
- Dividend Yield
- CADL N/A
- AQST N/A
- EPS Growth
- CADL N/A
- AQST N/A
- EPS
- CADL N/A
- AQST N/A
- Revenue
- CADL N/A
- AQST $57,561,000.00
- Revenue This Year
- CADL N/A
- AQST N/A
- Revenue Next Year
- CADL N/A
- AQST $35.72
- P/E Ratio
- CADL N/A
- AQST N/A
- Revenue Growth
- CADL N/A
- AQST 13.79
- 52 Week Low
- CADL $1.45
- AQST $2.24
- 52 Week High
- CADL $14.60
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CADL 49.50
- AQST 58.48
- Support Level
- CADL $7.85
- AQST $2.71
- Resistance Level
- CADL $8.69
- AQST $3.39
- Average True Range (ATR)
- CADL 0.54
- AQST 0.21
- MACD
- CADL -0.02
- AQST 0.08
- Stochastic Oscillator
- CADL 54.55
- AQST 80.32
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.